Open AccessJournal Article
Marine natural products as anticancer drugs
TLDR
This review highlights several marine natural products and their synthetic derivatives that are currently undergoing clinical evaluation as anticancer drugs.Abstract:
The chemical and biological diversity of the marine environment is immeasurable and therefore is an extraordinary resource for the discovery of new anticancer drugs. Recent technological and methodologic advances in structure elucidation, organic synthesis, and biological assay have resulted in the isolation and clinical evaluation of various novel anticancer agents. These compounds range in structural class from simple linear peptides, such as dolastatin 10, to complex macrocyclic polyethers, such as halichondrin B; equally as diverse are the molecular modes of action by which these molecules impart their biological activity. This review highlights several marine natural products and their synthetic derivatives that are currently undergoing clinical evaluation as anticancer drugs.read more
Citations
More filters
Journal ArticleDOI
Besarhanamides A and B from the marine cyanobacterium Lyngbya majuscula.
TL;DR: Besarhanamides A and B are fatty acid amides purified from the marine cyanobacterium, Lyngbya majuscula, collected from Pulau Hantu, Singapore and exhibited moderate toxicity with LD(50) at 13 microM in the brine shrimp toxicity bioassay.
Journal ArticleDOI
Direct effects of fascaplysin on human umbilical vein endothelial cells attributing the anti-angiogenesis activity
TL;DR: The results suggest that the anti-angiogenesis activity of fascaplysin is through the direct effects of cell cycle arrest and apoptosis on HUVEC.
Journal ArticleDOI
Furano-sesquiterpene from soft coral, Sinularia kavarittiensis: induces apoptosis via the mitochondrial-mediated caspase-dependent pathway in THP-1, leukemia cell line
TL;DR: The results show that MDTFC could efficiently and selectively inhibit the proliferation of several human cancer cell lines and especially on leukemia cells and the present compound of marine origin might have a therapeutic value against human cancer cells.
Journal ArticleDOI
Membrane-active peptides from marine organisms--antimicrobials, cell-penetrating peptides and peptide toxins: applications and prospects.
TL;DR: The current review will help in identifying the MAPs from marine organisms with crucial post-translational modifications that can be used as template for designing novel therapeutic agents and drug-delivery vehicles for treatment of human diseases.
Journal ArticleDOI
Total Synthesis of the Biologically Active, Naturally Occurring 3,4‐Dibromo‐5‐[2‐bromo‐3,4‐dihydroxy‐6‐(methoxymethyl)benzyl]benzene‐1,2‐diol and Regioselective O‐Demethylation of Aryl Methyl Ethers
TL;DR: In this paper, a natural product, 3,4-Dibromo-5-[2-bromo]-4,5-dimethoxyphenyl)methanol (5) with an overall yield of 34% was synthesized for the first time.
References
More filters
Journal ArticleDOI
Environmental Genome Shotgun Sequencing of the Sargasso Sea
J. Craig Venter,Karin A. Remington,John F. Heidelberg,Aaron L. Halpern,Doug Rusch,Jonathan A. Eisen,Dongying Wu,Ian T. Paulsen,Karen E. Nelson,William C. Nelson,Derrick E. Fouts,Samuel Levy,Anthony H. Knap,Michael W. Lomas,Kenneth H. Nealson,Owen White,Jeremy Peterson,Jeff Hoffman,Rachel Parsons,Holly Baden-Tillson,Cynthia Pfannkoch,Yu-Hui Rogers,Hamilton O. Smith +22 more
TL;DR: Over 1.2 million previously unknown genes represented in these samples, including more than 782 new rhodopsin-like photoreceptors are identified, suggesting substantial oceanic microbial diversity.
Journal ArticleDOI
Natural Products as Sources of New Drugs over the Period 1981−2002
TL;DR: From the data presented, the utility of natural products as sources of novel structures, but not necessarily the final drug entity, is still alive and well, and in the area of cancer, the percentage of small molecule, new chemical entities that are nonsynthetic has remained at 62% averaged over the whole time frame.
Journal ArticleDOI
Marine Natural Products and Related Compounds in Clinical and Advanced Preclinical Trials
David J. Newman,Gordon M. Cragg +1 more
TL;DR: There are now significant numbers of very interesting molecules that have come from marine sources, or have been synthesized as a result of knowledge gained from a prototypical compound, that are either in or approaching Phase II/III clinical trials in cancer, analgesia, allergy, and cognitive diseases.
Journal ArticleDOI
Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle.
TL;DR: This review describes the biochemistry of tubulin, microtubules, and the mitotic spindle and describes the natural and synthetic agents which are known to interact with tubulin.